Holen Sie sich die Stockscreener-App
32.53
5.07%
1.57
Handel nachbörslich:
32.53
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
LENZ Therapeutics: Ready To Test Its Potential (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics reports results of stockholder vote By Investing.com - Investing.com Nigeria
LENZ Therapeutics reports results of stockholder vote - Investing.com
LENZ Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Citi maintains Buy rating, $45 target on LENZ Therapeutics stock By Investing.com - Investing.com South Africa
Citi maintains Buy rating, $45 target on LENZ Therapeutics stock - Investing.com
Two Sigma Investments LP Has $493,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Transcript : LENZ Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZLENZ Therapeutics Reports Third Quarter 2024 Financial Results - mx.advfn.com
Jane Street Group LLC Cuts Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
BNP Paribas Financial Markets Sells 859 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN
Deutsche Bank AG Purchases 4,370 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Holdings Boosted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Holdings Decreased by Ameriprise Financial Inc. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Analysts - Defense World
LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks
7,447 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by D. E. Shaw & Co. Inc. - Defense World
LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision - Investing.com Canada
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics Showcases Revolutionary Eye Drop Treatment at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Northern Trust Corp Raises Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss - insights.citeline.com
Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Tower Research Capital LLC TRC Has $54,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment - BioSpectrum Asia
LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers
LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment - Yahoo Finance
Raymond James Financial Inc. Takes $245,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Leerink Partnrs Analysts Raise Earnings Estimates for LENZ - Defense World
HC Wainwright Issues Negative Estimate for LENZ Earnings - Defense World
Leerink Partnrs Has Negative Outlook of LENZ FY2028 Earnings - Defense World
LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Positive Estimate for LENZ FY2029 Earnings - Defense World
Lenz Therapeutics inks $125M licensing deal with Lotus - Axios
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by Wells Fargo & Company MN - Defense World
LENZ Grants Lotus Licensing Rights to Presbyopia Treatment in South Korea, Southeast Asia - marketscreener.com
LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia - The Manila Times
Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive - Investing.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of “Buy” by Brokerages - Defense World
LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Market Recap Check: LENZ Therapeutics Inc (LENZ)’s Negative Finish at 25.89, Up/Down -11.03 - DWinneX
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times
LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq
First-Ever Presbyopia Eye Drop Treatment: LENZ Therapeutics Reveals Latest Progress at BofA Conference - Stock Titan
Barclays PLC Increases Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
JPMorgan Chase & Co. Purchases 2,643 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Renaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Legal & General Group Plc Has $252,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 - The Manila Times
LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq
Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan
Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight - The Globe and Mail
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):